Patent Ever Greening
DOI:
https://doi.org/10.61841/bfp38r47Keywords:
Patent, Ever greening, Novartis, PharmaceuticalsAbstract
Patent is an exclusive privilege to reward the true and first inventors of new inventions. To be patentable, an invention must be novel, involving inventive step and of industrial application. Theoretically patents exist to promote the diffusion of innovative knowledge. The patent system provides necessary incentives for investment in research and encourages inventors to engage in new lines of R & D, thus it stimulating further creativity. It is considered as exclusive right and not as a monopoly, because in the scheme of patents there are inbuilt checks and balances to prevent the abuse of patents such as compulsory licensing, permitted use etc. However, the recent trend in the patent system shows that there is a tendency to evergreen the patent rights, especially in the pharmaceutical sector, by making trivial modifications and changes. Drug companies generally do ever-greening, by filing new patent applications, tweaking existing molecules to show novelty. Ever-greening of patent is a phrase used to label practices that have developed in certain jurisdictions wherein a trifling change is made to an existing product, and claimed as a new invention. The present paper discusses about the patents with a special emphasis on ever-greening of patents. The landmark judicial decision in Novartis A G v. Union of India will also be analyzed.
Downloads
References
[1] D. Bhowmik, K. P. S. Kumar, S. Paswan, and S. Srivastava, “Tomato-A Natural Medicine and Its Health
Benefits,” Phytojournal, 2012.
[2] I. K. Arah, H. Amaglo, E. K. Kumah, and H. Ofori, “Preharvest and postharvest factors affecting the quality
and shelf life of harvested tomatoes: A mini review,” International Journal of Agronomy. 2015.
[3] G. Zhu et al., “Rewiring of the Fruit Metabolome in Tomato Breeding,” Cell, 2018.
[4] P. Paduchuri, S. Gohokar, B. Thamke, and M. Subhas, “Transgenic Tomatoes – a Review,” Int. J. Adv.
Biotechnol. Res., 2010.
[5] T. Hirai, G. Fukukawa, H. Kakuta, N. Fukuda, and H. Ezura, “Production of recombinant miraculin using
transgenic tomatoes in a closed cultivation system,” J. Agric. Food Chem., 2010.
[6] W. Lim, R. Miller, J. Park, and S. Park, “Consumer Sensory Analysis of High Flavonoid Transgenic
Tomatoes,” J. Food Sci., 2014.
[7] A. Gerszberg, K. Hnatuszko-Konka, T. Kowalczyk, and A. K. Kononowicz, “Tomato (Solanum lycopersicum
L.) in the service of biotechnology,” Plant Cell, Tissue and Organ Culture. 2015.
[8] T. Lin et al., “Genomic analyses provide insights into the history of tomato breeding,” Nature Genetics. 2014.
[9] L. Liu, Z. Shao, M. Zhang, and Q. Wang, “Regulation of carotenoid metabolism in tomato,” Molecular Plant.
2015.
[10] C. Zhang, R. Wohlhueter, and H. Zhang, “Genetically modified foods: A critical review of their promise and
problems,” Food Sci. Hum. Wellness, 2016.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
